
<![CDATA[Navigating ARANOTE Trial Findings and Insurance for Prostate Cancer]]>
Darolutamide (Nubeqa) is an androgen receptor inhibitor that, when combined with androgen-deprivation therapy (ADT), has demonstrated significant efficacy in treating metastatic hormone-sensitive prostate cancer (mHSPC). Tian Zhang, MD, MHS, an associate …